title: Improving mitochondrial bioenergetics under ischemic conditions increases warm ischemia tolerance in the kidney.
abstract: Ischemia time during partial nephrectomy is strongly associated with acute and chronic renal injury. ATP depletion during warm ischemia inhibits ATP-dependent processes, resulting in cell swelling, cytoskeletal breakdown, and cell death. The duration of ischemia tolerated by the kidney depends on the amount of ATP that can be produced with residual substrates and oxygen in the tissue to sustain cell function. We previously reported that the rat can tolerate 30-min ischemia quite well but 45-min ischemia results in acute kidney injury and progressive interstitial fibrosis. Here, we report that pretreatment with SS-20 30 min before warm ischemia in the rat increased ischemia tolerance from 30 to 45 min. Histological examination of kidney tissues revealed that SS-20 reduced cytoskeletal breakdown and cell swelling after 45-min ischemia. Electron microscopy showed that SS-20 reduced mitochondrial matrix swelling and preserved cristae membranes, suggesting that SS-20 enhanced mitochondrial ATP synthesis under ischemic conditions. Studies with isolated kidney mitochondria showed dramatic reduction in state 3 respiration and respiratory control ratio after 45-min ischemia, and this was significantly improved by SS-20 treatment. These results suggest that SS-20 increases efficiency of the electron transport chain and improves coupling of oxidative phosphorylation. SS-20 treatment after ischemia also significantly reduced interstitial fibrosis. These new findings reveal that enhancing mitochondrial bioenergetics may be an important target for improving ischemia tolerance, and SS-20 may serve well for minimizing acute kidney injury and chronic kidney disease following surgical procedures such as partial nephrectomy and transplantation.
authors.affiliation: Research Program in Mitochondrial Therapeutics, Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York hhszeto@med.cornell.edu.
authors.forename: Hazel H
authors.initials: HH
authors.lastname: Szeto
authors.affiliation: Research Program in Mitochondrial Therapeutics, Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York.
authors.forename: Shaoyi
authors.initials: S
authors.lastname: Liu
authors.affiliation: Research Program in Mitochondrial Therapeutics, Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York.
authors.forename: Yi
authors.initials: Y
authors.lastname: Soong
authors.affiliation: Research Program in Mitochondrial Therapeutics, Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York.
authors.forename: Alexander V
authors.initials: AV
authors.lastname: Birk
mesh_terms: D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000818:Animals; D004353:Drug Evaluation, Preclinical; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000517:prevention & control*; D052096:Warm Ischemia
chemical_list: D009842:Oligopeptides; C520830:phenylalanyl-arginyl-phenylalanyllysinamide; D000255:Adenosine Triphosphate
keywords: SS-20; Szeto-Schiller peptides; acute kidney injury; chronic kidney disease; ischemia-reperfusion injury; mitochondrial cristae; mitochondrial swelling